Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop
...t #235 Oral presentation: Friday, February 27, 2:00 pm ET
Bortezomib, dexamethasone, cyclophosphamide, lenalidomide
(VDCR) has high efficacy in frontline MM
Lead investigator: Shaji Kumar, M.D., Associate Professor of Medicine, Mayo Clinic, Rochester, ...
Drug combination improves or stabilizes disease for relapsed multiple myeloma patients
... Food and Drug Administration (FDA) has approved the use of thalidomide and lenalidomide
to be given with dexamethasone for previously treated cases of multiple mye...e dose that was used in the registration trial that led to FDA approval for lenalidomide
in previously treated myeloma patients. "We're getting good results with le...
Lenalidomide safe as single therapy for elderly CLL patients
... SAN FRANCISCO ― The oral medication lenalidomide
is safe and well-tolerated for elderly patients with chronic lymphocytic le... stable disease and continue on therapy, and two had their CLL progress.
also rapidly reduced the number of circulating lymphocytes the hallmark of...
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
...e Center, Hall A Poster Board no.: I-115
MONDAY, DECEMBER 8th Abstract 3691 TITLE: Phase I Results of Perifosine (KRX-0401) in Combination with lenalidomide
and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Session Name: Myeloma - Therapy, excluding Transplantation Poster I...
A new agent for the treatment of patients with myelodysplastic syndrome; and more
...ssion profiling to identify a molecular signature that predicts response to lenalidomide
in patients without chromosome 5q deletions. This suggests that these patie..., et al. (2008) An erythroid differentiation signature predicts response to lenalidomide
in myelodysplastic syndrome. PLoS Med 5(2): e35.
PLEASE ADD THE LINK TO ...
3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
...a-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.
The three-pronged regimen of Velcade, lenalidomide
(Revlimid) and dexamethasone referred to as Rev/Vel/Dex has achieved an overall response rate of 98 percent in 42 patients evaluated thus far in a P...
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
 - Board #323-I
A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial
of Perifosine (KRX-0401) in Combination with lenalidomide
in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated
Andrzej Jakubowiak, Todd Zimmerman, Melissa Alsina, P...
JCI online early table of contents: Dec. 6, 2007
...e Parseval and colleagues working for Celgene Corporation.
In the study, lenalidomide
and pomalidomide, immunomodulatory anticancer drugs, were both shown to be ...athies other than SCD, such as beta-thalassemia.
TITLE: Pomalidomide and lenalidomide
regulate erythropoiesis and fetal hemoglobin production in human CD34+ cell...
Drug combination effective against multiple myeloma, researchers show
...ents with myeloma received either a combination of lenalidomide
(Revlimid(r)) and the steroid dexamethasone or dexamethasone plus a placebo.
"Those taking the lenalidomide
combination had a median time to disease progressi...ngland Journal of Medicine, led to the approval of lenalidomide
and dexamethasone for previously treated patients ...
Penn's Abramson Cancer Center part of major phase III study for myeloma
...lood-making cells of bone marrow. The findings show that with the oral drug lenalidomide
(REVLIMID), in combination with the steroid dexamethasone, patients signifi...ies, patients for whom all previous treatments had failed were given either lenalidomide
plus dexamethasone a potent synthetic steroid or dexamethasone with place...
Lenalidomide in Medical Technology
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03)
Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival
Advantage for Patients with Multiple Myeloma
SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- Celgene
Corporation announced that the Eastern Cooperative Oncology Group
(ECOG) has reported that its Data Monitoring Committee's (DMC)
review of preliminary results from a large, randomized clinical
trial for patients with newly diagnosed mu...
Low-Dose Steroid Combined With Lenalidomide Prolongs Survival
Compared With High-Dose Steroid for Multiple Myeloma Treatment
WASHINGTON, April 4, 2007-Preliminary results from a large,
randomized clinical trial for patients with newly diagnosed
multiple myeloma, a cancer typically found in bone marrow, has
shown that the use of a low dose of the steroid dexamethasone
(Decadron ®), in combination with lenalidomide
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
... clinical trial of carfilzomib in combination with lenalidomide
and dexamethasone during the "Lymphoma and Plasma ...scalating trial of carfilzomib in combination with lenalidomide
and low-dose dexamethasone in relapsed and refractory patients. The combination of carfilzomib and lenalidomide
is well tolerated and encouraging response rates h...
Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
...cted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase Ib clinical trial of carfilzomib in combination with lenalidomide
and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical tr...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Abstract #8542: Panobinostat + lenalidomide
and dexamethasone Phase I trial in multiple myelom...ation of panobinostat (LBH589) in combination with lenalidomide
and dexamethasone, the 5 mg and 10 mg doses of pan...ndo, FL.
Spencer A, et al. Panobinostat + lenalidomide
and dexamethasone Phase I trial in multiple myelom...
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
...ly treated with dexamethasone; 99% of patients were previously treated with lenalidomide
(Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had pri...:
Phase 1 Updated Results of Perifosine (KRX-0401) in Combination with lenalidomide
and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma ...
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
...ly treated with dexamethasone; 98% of patients were previously treated with lenalidomide
(Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had pri...bstract 3691: Phase 1 Results of Perifosine (KRX-0401) in Combination with lenalidomide
and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma ...
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
...dy of VELCADE, dexamethasone, cyclophosphamide
(VcDCR) in patients with previously untreated mult...ycles; dexamethasone at 40 mg on
days 1, 8 and 15; lenalidomide
at 15 mg on days 1 through 14; and
cyclophosphamid... (1) Evaluation of VELCADE, dexamethasOne, and lenalidomide
with or without
cyclophosphamide Using Targeted In...
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
... multi-center study of single-agent carfilzomib in patients
who have previously failed at least two prior treatments, containing
bortezomib and either lenalidomide
or thalidomide, and are refractory to their
last treatment. Data from a second ongoing Phase 2 clinical trial of
single-agent carfilzomib in relapsed...
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
...oteolix's lead anti-cancer
agent, carfilzomib (PR-171), in combination with lenalidomide
dexamethasone in patients with relapsed multiple myeloma. Carfilzomib
s...ed in the trial have received prior
treatment(s) with bortezomib and either lenalidomide
or thalidomide and are
refractory to their last treatment.
A second open-...
Lenalidomide in Biological News
Lenalidomide in Biological Technology